Head-to-head

BPC-157 vs MOTS-c

A field-by-field comparison of BPC-157 and MOTS-c drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. They belong to different categories — recovery & repair and metabolic — so this page focuses on what each one actually does rather than which is "better".

BPC-157 vs MOTS-c at a glance

Attribute	BPC-157	MOTS-c
Category	Recovery & repair	Metabolic
Evidence grade	Emerging	Emerging
Also known as	Body Protection Compound 157, PL 14736	Mitochondrial open reading frame of the 12S rRNA-c, MT-RNR1-encoded peptide
Chain	15 amino acids (GEPPPGKPADDAGLV)	16 amino acid mitochondrial-derived peptide
Mechanism	Appears to upregulate growth-hormone receptor expression in tendon fibroblasts and promote angiogenesis via the VEGFR2–Akt–eNOS pathway, accelerating the formation of new blood vessels at an injury site. It also modulates nitric oxide signalling and appears protective of the gut lining.	Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress.
Reported benefits	Faster tendon, ligament and muscle healing in rodent models · Protective effect on the gastrointestinal lining, including NSAID-induced damage · Reduced local inflammation around injury sites · Anecdotal relief from tendinopathy and joint pain	Improved insulin sensitivity and glucose disposal in rodent models · Enhanced fat oxidation and reduced fat accumulation · Exercise-mimetic effects on metabolism and physical capacity · Potential protection against diet-induced metabolic dysfunction
Reported side effects	Injection-site irritation · Transient dizziness or nausea · Unknown long-term safety profile	Limited human safety data · Injection-site irritation · Possible hypoglycaemia in susceptible individuals
Half-life	Approximately 4 hours (stable oral form debated)	Estimated minutes to a few hours
Administration	Subcutaneous injection; oral capsules used for gut-specific goals	Subcutaneous injection; oral capsules are marketed but less validated
Dosing overview	Commonly cited in literature at 200–500 mcg once or twice daily for 4–8 weeks	Commonly cited at 5–10 mg daily, often for 4–12 week cycles
Storage	Lyophilised powder refrigerated; reconstituted vials 2–8 °C, used within ~30 days	Lyophilised powder refrigerated; reconstituted vials 2–8 °C and used within ~30 days
Legal status	Not FDA-approved. Research-chemical status in most countries; prohibited in sport.	Research chemical; not approved as a drug.

Key differences between BPC-157 and MOTS-c

Different categories, different goals

BPC-157 is indexed under recovery & repair, while MOTS-c sits under metabolic. They are not substitutes for one another: BPC-157 is described as "A synthetic fragment of a protein found in gastric juice, widely used in the recovery community for tendon, gut and soft-tissue complaints." and MOTS-c as "A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects."

Mechanism of action

BPC-157: Appears to upregulate growth-hormone receptor expression in tendon fibroblasts and promote angiogenesis via the VEGFR2–Akt–eNOS pathway, accelerating the formation of new blood vessels at an injury site. It also modulates nitric oxide signalling and appears protective of the gut lining. MOTS-c: Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress.

Half-life and dosing frequency

BPC-157 is listed at approximately 4 hours (stable oral form debated); MOTS-c at estimated minutes to a few hours. That difference is what drives the reported schedules: Commonly cited in literature at 200–500 mcg once or twice daily for 4–8 weeks versus Commonly cited at 5–10 mg daily, often for 4–12 week cycles

Route of administration

BPC-157 is administered by subcutaneous injection; oral capsules used for gut-specific goals. MOTS-c is administered by subcutaneous injection; oral capsules are marketed but less validated.

Legal and regulatory status differs

BPC-157: Not FDA-approved. Research-chemical status in most countries; prohibited in sport. MOTS-c: Research chemical; not approved as a drug. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.

Handling and storage

BPC-157 is stored lyophilised powder refrigerated; reconstituted vials 2–8 °c, used within ~30 days. MOTS-c is stored lyophilised powder refrigerated; reconstituted vials 2–8 °c and used within ~30 days.

What BPC-157 and MOTS-c have in common

Evidence grade: both listed as Emerging

Both profiles list the same reported side effects: injection-site irritation.

Each compound in brief

BPC-157

Recovery & repair · Emerging evidence

A synthetic fragment of a protein found in gastric juice, widely used in the recovery community for tendon, gut and soft-tissue complaints.

Considerations: Nearly all evidence is preclinical (rodent); robust human trials are absent · Injected near the injury site is the common anecdotal practice, though systemic effects are proposed · Banned by WADA for competing athletes

MOTS-c

Metabolic · Emerging evidence

A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects.

Considerations: Most evidence is preclinical; human trials are small and early-phase · Short half-life may require daily or twice-daily dosing · Bioavailability of oral forms is uncertain compared with injection